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Abstract 
 
Alzheimer’s disease (AD) is the leading cause of dementia and death in the United States. 
AD is characterized by extracellular amyloid plaques and intracellular neurofibrillary tangles. 
Patients are classified into early-onset AD (EOAD), which are developed before 65, and late-onset 
AD (LOAD), developed after 65. Three causative genes were identified for EOAD: amyloid 
precursor protein (APP), presenilin (PSEN) 1 and 2. However, there are no causative genes found 
for LOAD. Risk factors of AD are complicated, including aging, family histories, high cholesterol 
levels, high blood pressure, brain injuries, and genetic risk factors. Recent genome-wide 
association studies have identified a set of genetic risk factors for LOAD, including the triggering 
receptor expressed on myeloid cells 2 (TREM2) and apolipoprotein E (APOE). Studies have 
identified several rare variants of TREM2 to increase the risk of developing LOAD by 2-4-fold. 
In the central nervous system (CNS), microglia play an important role in responding to plaque 
accumulation during AD pathology. TREM2, as the receptor of microglia, was proposed to affect 
microglia functions, including survival, proliferation, chemotaxis, and phagocytosis. TREM2 was 
also found to impair the activation of homeostatic microglia and energy metabolism of microglia 
cells. This review summarized previous studies in the past 5 years and elucidated the current 
understanding of the role of TREM2 in microglia function and AD pathology, as well as 
 v 
opportunities and challenges of targeting of TREM2 as a potential therapeutic strategy, which is 
of high public health significance. 
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1.0 Introduction 
As the most common form of dementia, Alzheimer’s Disease (AD) is officially identified 
as the sixth leading cause of death in the United State. In 2019, 5.8 million of US population are 
estimated to live with AD, with 5.6 million of them aged 65 and older [1]. The number is growing 
rapidly with the population getting older. It is reported that deaths caused by AD of all ages have 
increased 145% from 2000 to 2017 [2]. According to the age of disease onset, two types of AD 
are classified: early-onset AD (EOAD) which were developed before 65 and late-onset AD 
(LOAD) which were developed after 65, with LOAD representing about 95% of all the cases. 
There are two morphological hallmarks of AD: extracellular deposits of β-amyloid peptide (Aβ) 
plaques and intracellular neurofibrillary tangles of tau protein [3]. 
Similar to other neurodegenerative diseases, aging is believed to be one of the most 
important risk factor but not direct cause of AD [4]. It has been reported that of the total US 
population, 3% of the population aged 65-74, 17% of the population aged 75-84, and 32% of the 
population aged 85 and older developed AD [1]. Aβ plaques and neurofibrillary tangles are also 
observed in healthy-aging brains [5]. Other risk factors, such as environmental exposures, 
lifestyles, diet, traumatic brain injury, and other systemic diseases are also reported to be involved 
in AD [5]. EOAD, or familial AD are widely believed to be linked with gene mutations of amyloid 
precursor protein (APP) and presenilin (PSEN) 1 and 2 that directly or indirectly increase 
production of toxic Aβ peptides. However, there is no causative gene mutations identified for 
LOAD. According to genome-wide association studies (GWAS), more than 30 risk loci for LOAD 
are identified [6], half of which are associated with immune response, such as apolipoprotein E 
(APOE) and triggering receptor expressed on myeloid cells 2 (TREM2) [7]. 
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APOE, mostly secreted by astrocytes, plays an important role in lipid metabolism, which 
is an essential part of immune response. There are three alleles of APOE: APOEε2, APOEε3, and 
APOEε4, accounting for about 10%, 70%, and 20%, respectively [8]. The three alleles have 
different amino acids at position 112 and 158: the ε2 allele has cysteine (Cys) at both positions, 
the ε3 allele has a Cys at position 112 and an arginine (Arg) at position 158, while the ε4 allele has 
Arg at the two positions. The ε2 allele was found to be linked with decreased risk of developing 
AD and later disease onset, while one copy of ε4 allele was associated with increasing AD risk by 
3- to 4-fold. The ε4 allele was identified by previous studies to have reduced ability on Aβ binding 
and clearing compared to the ε2 and ε3 allele [8-10]. TREM2 is a cell surface receptor of the 
immunoglobulin superfamily that is expressed by microglia in the central nervous system (CNS). 
Several rare variants of TREM2 have been identified to be associated with increasing the risk of 
developing AD by 2- to 4-fold [10]. One of these variants, the most well-studied one, rs75932628 
variant (Arg-to-His change at amino acid 47, or R47H) is reported to significantly increase the risk 
of developing AD in North American and European population [11, 12]. In contrast, in Chinese 
population, there is no association between R47H TREM2 and AD [13], but rs2234255 variant 
(His-to-Tyr change at amino acid 157, or H157Y) was identified to increase the risk of developing 
AD (odds ratio: 11.01, p = 0.02) [14]. However, no evidence found between H157Y and AD risk 
in Caucasian cohort [15], suggesting the effects of TREM2 rare variants might be population-
specific. A case-control study, including 36,790 controls and 48,343 AD patients reported 
association between rs143332484 variant (Arg-to-His change at amino acid 62, or R62H) and AD 
risk (odds ratio 1.67, p = 1.55 X 10-14) [12]. R67H TREM2 was found to reduce microglial 
response of Aβ plaques and increase microglial accumulation of autophagosomes [16, 17]. AD 
related variants of TREM2, such as R47H and R62H, were found to change the secondary structure 
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and impair ligands binding [18]. However, there do exist other variants, like T96K, which are 
probably gain-of-function mutations according to the structural and binding studies [18]. 
This review focuses on the role of TREM2 on microglial function and AD pathology. 
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2.0 TREM2 
TREM2, a member of the TERM family, is a cell surface transmembrane receptor with an 
extracellular Ig-like domain, a cytoplasmic tail, and a transmembrane domain [10]. In human, the 
TREM2 gene is located on chromosome 6p21 near some other TREM and TREM-like genes and 
encodes 230 amino acids [19]. TREM2 is expressed on resident macrophages, infiltrating and 
inflammatory macrophages, cerebrospinal fluid (CSF) monocytes, and dendritic cells [20, 21]. In 
the central nervous system (CNS), TREM2 is entirely expressed by microglia; its expression is 
strong in the basal ganglia, corpus callosum, spinal cord, and medulla oblongata [10]. Retinoid X 
receptor (RXR), which binds upstream of TREM2 locus, is reported to regulate the expression [22, 
23]. Treatment of bexarotene, an RXR agonist, enhanced the expression of TREM2 mRNA in the 
cortex of AD mice [23]. Expression of TREM2 is affected by inflammation; pro-inflammatory 
molecules such as lipopolysaccharide (LPS) downregulated TREM2 expression, but anti-
inflammatory molecules upregulated TREM2 expression in vitro [24-26]. During pathological 
processes, such as AD, traumatic brain injury (TBI), Amyotrophic lateral sclerosis (ALS), and 
Parkinson’s disease (PD), TREM2 was found upregulated [24, 27-29]. In addition, aging is also a 
regulator of TREM2 expression [30]. 
Exact ligands that bind and activate TREM2 remains unclear. The extracellular region of 
TREM2 with an immunoglobulin domain is suggested to bind microbial products, such as LPS 
[31, 32]. As a member of the TREM family, TREM2 can also bind lipids because of the potential 
phospholipid binding site [18]. The ability of lipid-binding allows TREM2 to recognize and bind 
phosphatidylserine on apoptotic cells and debris [31, 33]. Some previous studies found TREM2 is 
able to bind lipoproteins including high-density lipoproteins (HDL), low-density lipoproteins 
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(LDL), and apolipoproteins, such as APOE [9, 11, 16, 34, 35]. An in vitro study also reported that 
TREM2 can bind to Aβ oligomers directly. Evidence suggested that Aβ enhances TREM2-DAP12 
interaction, and additionally, TREM2 deletion impaired Aβ degradation both in vitro and in vivo 
[36]. 
As shown in Figure 1, upon ligand binding, intracellular signals are conveyed through 
DNAX-activating protein of 12 kDa (DAP12), also known as TYROBP (tyrosine kinase-binding 
protein). The cytosolic immunoreceptor tyrosine-based activation motifs (ITAMs) on DAP12 will 
recruit the tyrosine protein kinase SKY, which leads to the activation of phosphoinositide 3-kinase 
(PI3K) - AKT pathway and phosphorylation of linker for activation of T-cells family member 1 
(LAT) and/or LAT2, which recruit other signaling adaptors such as phospholipase Cγ (PLCγ), 
diacylglycerol (DAG), and protooncogene vav (VAV1). PLCγ further degrades 
phosphatidylinositol-3,4,5-trisphosphate (PIP3) to inositol trisphosphate (IP3), thus mobilizing 
Ca2+; DAG activates the protein kinase Cθ (PKCθ); VAV1 induces actin remodeling that controls 
migration and adhesion [37-40]. All these signals and pathways help survival, proliferation, 
phagocytosis, and release of cytokines and chemokines [17, 30, 32, 41-43]. Full length TREM2 
can be cleaved by a disintegrin and metalloproteinase domain-containing protein (ADAM10) and 
γ-secretase, thus releasing soluble TREM2 (sTREM2) [41, 44, 45]. 
The exact biological and pathological role of sTREM2 is not clear. sTREM2 was found in 
human CSF and the level increased in the CSF of LOAD patients [46, 47]. Some proposed it as a 
decoy receptor against TREM2 [43]. From cell culture, sTREM2 helped survival of bone marrow-
derived macrophages [41]. Zhong et al. firstly suggested that sTREM2 plays an important role in 
promoting microglia survival and regulating inflammatory responses [43]. In addition, sTREM2 
was found to reduce Aβ plaque load and improve spatial memory [48]. 
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Figure 1: TREM2 ligands and signaling pathways. 
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3.0 TREM2 and Microglial Function 
3.1 Proliferation 
TREM2 expression and TREM2-induced signaling are essential in regulating microglia 
cell numbers, their survival, and proliferation. In primary microglial culture, cell numbers were 
reduced significantly when TREM2 was downregulated [25]. Wang et al. used a well-
developed proliferation marker, Ki-67, with 5XFAD mouse model, and suggested that Aβ-
induced microgliosis mostly depends on the proliferation of CNS-resident microglia, instead 
of peripheral blood monocytes. They also observed that the number of plaque-associated Ki-
67+ microglia was decreased dramatically in case of TREM2 knockout, indicating that 
proliferation of local microglia around the plaques were also impaired with TREM2 deficiency 
[20]. Another study assessed the loss of plaque-associated microglia at both early and late 
stages of AD pathology. They observed no significant change of proliferating microglia in 2-
month-old mice, but significant reduction in 8-month-old TREM2 knockout mice compared to 
wildtype mice. They divided the cells into CD45high and CD45low according to their expression 
level of CD45, and found that TREM2 loss of function affects the number of CD45high 
microglia throughout all AD progression, but affects CD45low cells only in the late stages of 
AD progression, suggesting the role of TREM2 in AD is disease-stage-dependent [49]. 
TREM2 also promotes microglial survival. Using TREM2 knockout in vivo model and 
TREM2 knockdown in vitro model, Zheng et al. demonstrated the relationship between 
TREM2/DAP12 signaling and Wnt/β-catenin signaling pathway and explained how TREM2 
can promote the survival of microglia. β-catenin is an essential component of the Wnt signaling 
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pathway and important in maintaining a lot of biological activities, including cell survival. 
They proposed that in case of TREM2 deficiency, cell cycle is stopped at the G1/S transition 
and β-catenin becomes unstable, while TREM2 can inhibit the degradation of β-catenin 
through AKT/GSK3β signaling pathway, thus promoting microglial survival. Additionally, 
activation of Wnt/ β-catenin pathway by treating Wnt3a, LiCl, or TDZD-8 may rescue 
microglial survival in case of TREM2 loss-of-function [50]. With Aβ injection, microglial 
proliferation and caspase-3 activation were found to increase in wildtype (WT) mice but 
reduced in case of TREM2 deficiency [36]. Wang et al. investigated TREM2 deficiency and 
haploinsufficiency in 5XFAD mouse model and found the supporting role of TREM2 in 
microglial survival and proliferation together with colony stimulating factor-1 receptor (CSF-
1R) signaling [32]. 
3.2 Chemotaxis 
As the resident immune cells of CNS, microglia play an important role in responding 
to CNS injury, neuronal death, and certain diseases through rapid migration [51]. However, 
some recent studies have suggested that TREM2 loss of function may affect microglial 
chemotaxis. Mazaheri et al. analyzed the transcriptional profile of microglia from wildtype and 
TREM2 knockout mice. They reported the downregulation of Ccl2, Il1b, Tnf, Spp1, and Vegfa, 
which are potential targets of TREM2 and involved in cell motility [52]. In an ex vivo study 
with brain slice, the migration distance of microglia was reduced [52]. Also, migration towards 
the defined chemo-attractants is limited with TREM2 deletion and rescued when TREM2 re-
expressed [52]. Results from the in vivo study are consistent that with TREM2-deficiency, 
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microglial chemotaxis was reduced towards apoptotic neurons and extension of microglia 
processes was affected in TREM2 knockout mice [52]. Using high-resolution confocal and 
super-resolution microscopy, Yuan and their group observed that TREM2 or DAP12 
deficiency impaired microglial function of polarizing, moving towards and compacting the 
plaques. Phosphorylated tyrosine, the marker of downstream kinase activation and indicator of 
microglial polarization was found reduced [53]. 
3.3 Phagocytosis 
In CNS, TREM2 is expressed by microglia, which have a high phagocytic ability [54]. 
A lot of previous studies have demonstrated that TREM2 is involved in promoting microglial 
phagocytosis [22]. TREM2 loss of function have been associated with reduced phagocytosis 
of apoptotic neurons [55, 56]. Phagocytosis of Aβ is also impaired in both primary microglia 
and N9 microglial cell line with TREM2 deficiency [57]. Lee and their group developed 
transgenic mice (BAC-TREM2) with human TREM2 expressed in microglia and reported 
upregulation of some reactive microglial genes that are related to phagocytosis, like Lgals3 
[58]. However, Wang et al. suggested that TREM2 does not have direct effects on phagocytosis 
of Aβ or apoptotic cells but can still help microglia phagocytosis indirectly through supporting 
survival of activated microglia [32]. Consistently, Yuan et al. observed that Aβ phagocytosis 
by microglia was not changed in TREM2+/- mice and proposed that fail-to-build the microglia 
barrier around the plaques could be the reason for increased Aβ accumulation and AD risks 
with TREM2 mutations [53]. It is also possible that TREM2 interacts with other phagocytosis 
receptors, such as MerTK [59]. Collectively, it is confirmed by many studies that TRME2 
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plays an important role in microglia phagocytosis of Aβ and apoptotic neurons, but the 
mechanism of TREM2-dependent effects on such processes remains unclear. 
3.4 Cytokine Release 
Microglia are crucial mediators of inflammatory responses in CNS. In response to CNS 
injury or certain diseases, microglia regulate phagocytosis and secretion of inflammatory 
cytokines [60]. With Aβ exposure in wildtype microglia, Zhao and colleagues observed 
increased level of pro-inflammatory cytokines, like interleukin 6 (IL-6) and macrophage 
inflammatory protein 1 α (CCL3), and decreased level of anti-inflammatory cytokines, like 
Arg1. However, these Aβ-associated cytokine releases were impaired in microglia with 
TREM2 deletion, suggesting that TREM2 regulates Aβ-associated cytokine expression [36]. 
Deficiency of TREM2 or DAP12 is observed to exacerbate lipopolysaccharides (LPS)-induced 
pro-inflammatory responses [61]. 
3.5 Cell-cell Communication 
Microglia are found important in maintaining neural circuits during early stage of CNS 
development via phagocytosis of supernumerary synapses with receptor CX3CR1 or CR3 [62]. 
Previous studies have linked impaired synaptic pruning with weaker synaptic transmission and 
reduced functional connection. Microglia also regulate synaptic plasticity through brain-
derived neurotrophic factor (BDNF) and tropomyosin receptor kinase B (TrkB) signaling 
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pathways [63]. In addition, Liddelow et al. proposed that activated microglia may induce A1 
reactive astrocytes, which are toxic to the CNS, through cytokine release, including Il-1α, 
TNFα, and C1q. Formation of A1s impairs the normal function of promoting neuronal survival 
and phagocytosis, and induce death of oligodendrocytes and neurons [64]. 
Considering the vital role of microglia in synaptic pruning, some studies investigated 
the role of TREM2 in regulating such function and brain development. Recently, Filipello and 
colleague detected impaired defective synapse pruning and reduced number of microglia in the 
hippocampus in TREM2-deficient mice. They found that TREM2-deficient microglia in the 
hippocampus showed decreased internalization of synaptic markers in CD68+ phagolysosome 
structures. In cultured neurons and TREM2-deficient microglia, synapse elimination was 
impaired [65]. 
Another study identified an endogenous cellular ligand on neuron (TREM2-L), which 
TREM2 can directly bind, and suggested a pathway for direct microglia-neuron 
communication. Expression of TREM2-L on apoptotic neurons were increased, thus enhancing 
phagocytosis by microglia [66]. 
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4.0 TREM2 Importance in Activation States of Microglia 
As the resident immune cells in the CNS, microglia are continually detecting the 
environment in CNS and responding rapidly through inflammatory reaction. Normally, microglia 
have a ramified shape in resting state, and transform to an ameboid or hypertrophic morphology 
upon activated [67]. Activated microglia are considered both protective and harmful to the CNS. 
They secrete protective neurotrophic factors assisting phagocytosis of damaged neurons or cellular 
debris. If over activated, they secrete toxic molecules, including reactive oxygen species and nitric 
oxide [38]. 
Previous studies have identified two sequential steps of microglial activation. The first 
stage includes the activation of Tyrobp, Apoe, and B2m, along with decreased expression of 
homeostatic factors, including Cx3cr1, and P2ry12/P2ry13. The second stage involves energy 
metabolism and phagocytosis, such as Lpl, Cst7, and CD9, which was found impaired in case of 
TREM2 loss-of-function, suggesting TREM2-dependent [68]. This mechanism explains the 
findings that deficiency of TREM2 in microglia at late stages of AD, rather than early stages of 
disease, worsen the disease progression [32]. 
In healthy brains, microglia have a specific homeostatic molecular signature, which is 
regulated by transforming growth factor β (TGFβ) signaling. While under disease conditions, 
microglia lose such homeostatic signatures and functions, and displayed specific disease-
associated microglia (DAM) characteristics [16]. Holtman et al. demonstrated a disease-specific 
microglia molecular signature. (as shown in Figure 2) Primed microglia are associated with 
expression of cell surface markers, including Itgax, Lgals3, Axl, Clec7a, MHC class 2, and Cxcr4. 
[69] However, Zhou et al. demonstrated that signature of DAM in AD patients is different from 
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that in the 5xFAD model. In AD patients, some genes considered as homeostatic genes in mice 
were also upregulated, such as P2RY12, CX3CR1, and TMEM119. They also found upregulation 
of some genes, which are not part of DAM signature in mouse models, such as SORL1, A2M, and 
CHI3L1 [70]. Krasemann and colleague proposed a mechanism that TREM2-APOE pathway 
regulates the functional phenotype of microglia in disease progression. Activation of TREM2-
APOE pathway downregulates homeostatic phenotype of disease-associated microglia, thus 
unable to maintain homeostasis of CNS [16]. 
 
Figure 2: Specific gene expression networks with microglia activation by LPS or aging.  
(Figure from Holtman et al. 2015) [69] 
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There are a lot of researches done to understand how TREM2 regulate microglia activation 
states. In primary microglia, LPS treatment reduced expression of TREM2, and modulation of 
TREM2 levels enhanced expression of LPS-induced pro-inflammatory cytokine genes [25].  
Aβ treatment can also reduce expression of TREM2 in primary microglia [25]. It is also 
reported that microglia from APPPS1/Trem2-/- mice expressed increased number of TGFbr1, 
which is involved in maintaining resting microglia in vivo, suggesting that TREM2 loss of function 
might prevent the resting microglia from being activated [52]. Similarly, another study analyzed 
molecular signature of microglia using APPPS1/Trem2-/- mice and observed the suppression of 
AD-associated signature and significant upregulation of homeostatic mRNA signature [71]. 
Cantoni et al. studied how TREM2 regulates microglial activation in response to demyelination 
and found that compared to wild type mice, TREM2 knockout microglia were less activated with 
downregulation of activation markers MHC II and more resting morphology observed [72]. 
Over and above the role as a receptor, TREM2 itself can activate microglia. As mentioned, 
TREM2 can be cleaved by ADAM10 and generate sTREM2, which enhance pro-inflammatory 
responses through nuclear factor (NF)-κB pathway and promote survival of microglia through 
PI3K pathway [43]. It is also proposed that sTREM2 act as an inhibitor of TREM2 through 
competitive ligands binding. Some suggested that sTREM2 could be a biomarker of AD because 
concentration of sTREM2 was found increased in CSF of AD patients [47, 73]. 
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5.0 TREM2 Importance in Bioenergetic Regulation of Microglia 
Recently, several studies reported the association between TREM2 and microglial 
metabolic state. Microglia respond rapidly to changes in the CNS. Along with microglial 
activation, energy metabolism will be switched from oxidative phosphorylation to glycolysis, 
which enables microglial plasticity [74]. 
Kleinberger et al. reported a significant decrease in cerebral blood flow and brain glucose 
metabolism in TREM2 T66M (a variant related to frontotemporal dementia) knock-in mice [75]. 
Increased number of autophagic vesicles were found in microglia with TREM2 deficiency in 
5xFAD mice compared to microglia in 5xFAD mice (Figure 3 A and B) [17]. Nugent et al. 
demonstrated that loss-of TREM2 causes dysregulated cholesterol transport and metabolism in 
microglia. They found that TREM2 deficiency leads to failure of myelin cholesterol clearing and 
accumulation of cholesteryl ester, indicating impaired cholesterol transport in the brain system 
[76]. 
As for human patients, more autophagic vesicles were observed in microglia in AD patients 
with AD-associated TREM2 variants compared to other AD patients (Figure 3 C and D) [17]. 
Using AD patient iPSC-derived microglia with rare variants of TREM2, Piers et al. showed that 
human iPSC-microglia with rare TREM2 variants, such as the R47H risk variant, displayed 
significant metabolic deficits, including impaired mitochondrial respiratory function and failure of 
glycolytic immunometabolism switch. The defective PPARγ/p38MAPK signaling was identified 
responsible for this impairment [77]. 
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Figure 3: TREM2 deficiency increases autophagy in both 5xFAD mice and AD patients.  
(A) Transmission electron microscopy images of microglia from 8-month-old wildtype, TREM2 KO, 5xFAD, 
and TREM2 KO 5xFAD mice. (B) Average number of multivesicular and multilamellar structures. (C) 
Confocal images of brain sections from R47H-AD patients and controls. (D) Percentage of LC3+ microglia 
from postmortem specimens of AD patients with R47H variant and R62H variant.  
(Figures from Ulland et al. 2017) [17]. 
 
Ulland et al. reported decreased mammalian target of rapamycin (mTOR) signaling as well 
as markers for defective anabolic metabolism and energy production in microglia of TREM2 
knockout AD mice [17]. TREM2 was identified as the receptor for immune response that regulates 
metabolism of microglia during AD pathology through the mTOR signaling pathway, which 
supporting long-term cell growth, proliferation, and survival [17]. This mechanism provides an 
explanation for the impacts of TREM2 on microglial functions, including proliferation, migration 
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towards plaques, and phagocytosis of debris. The mTOR pathway also partially regulate 
autophagy, which is an intracellular recycling and degradation pathway for cellular components 
and energy homeostasis. Specifically, in response to extreme situations like cell starvation, 
autophagy helps maintaining cellular energy through breakdown and recycling of cellular 
components [78]. In case of mTOR impairment in TREM2-deficient microglia, autophagy is 
increased, and microglial clearance of Aβ would be enhanced in the short term. However, long-
term impairment of mTOR signaling may still damage microglial function, including survival and 
proliferation [32]. So, although increased autophagy might help reduce inflammation and plaque 
for a short period, in the long-term, defective mTOR signaling can still impair microglial survival 
and function in response to plaque load. In addition, activation of Dectin-1, a cell surface receptor, 
or treatment with creatine analog 1-carboxymethyl-2-iminoimidazo-lidine (cyclocreatine) could 
rescue the metabolic impairment. Microglia survival and migration were found improved with 
regulation of dietary cyclocreatine during Aβ accumulation [17]. 
It is widely believed that microglia are able to detect any injuries or stressful situations in 
the CNS environment and react rapidly to those signals. These researches and findings regarding 
changes about bioenergetic regulation of TREM2-deficient microglia provide a potential answer 
to their dysfunction in responding to plaque stress in AD brains. Further studies are required to 
have a better understanding of microglial biology. 
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6.0 TREM2 and Other Neurodegenerative Diseases 
TREM2 variants are risk factors for not only AD but also other neurodegenerative diseases, 
including polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 
(PLOSL; or Nasu-Hakola Disease), frontotemporal dementia (FTD), Parkinson’s disease (PD), 
and amyotrophic lateral sclerosis (ALS). 
PLOSL is progressive disorder characterized by bone abnormalities, including pain and 
weakened ankles, and early-onset dementia. Although patients were reported all over the world, 
PLOSL is still a rare disease: 1 to 2 cases per million people in Finland and over 100 cases reported 
in Japan. Biallelic mutations in TREM2 or TYROBP (or DAP12) are considered as causes for 
PLOSL. According to the first report of TREM2 and PLOSL, DAP12 mutations were found in 
79% patients and TREM2 mutations were reported in the other 21% patients [79]. A study in Italy 
has linked Q33X variant of TREM2 with amyloid accumulation in PLOSL [80]. Other rare variants 
of TREM2, such as E14X, W44X, W50C, W78X, G90VfsX99, A105RfsX84, V126G, and 
D134H, were also demonstrated as pathologic to PLOSL [81-84]. From immunohistochemistry 
study for PLOSL patients, amyloid plaques and neurofibrillary tangles were almost undetectable 
[85]. However, Kaivola et al. reported no significant differences of mental conditions between 
TYROBP deletion carriers and noncarriers in Finland cohort, indicating that heterozygous 
TYROBP deficiency is not strongly causative for dementia [86]. Similarly, another study 
investigated mutations in TYROBP in a Turkish cohort including 103 dementia patients and found 
no predicted mutations or variants, suggesting that TYROBP mutations are not a cause of cognitive 
decline in Turkish cohort [87]. 
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FTD refers to a group of brain disorders, which mostly affect the frontal or temporal lobes 
of the CNS. They are much less frequent than AD and less understood. Causes of FTD are 
unknown, but family history is one of the risk factors. Some TREM2 rare variants were reported 
as pathologic to FTD, including Q33X, R47H, Y38C, R47C, T66M, W198X, c.391+1G>A, and 
c.482+1G>A, while some other variants were related with unclear pathogenicity, such as A28V, 
D39N, R62C, and D86V [12, 88-92]. 
TREM2 R47H was identified as risk factor for PD and ALS by some researches as well. A 
study investigated sporadic ALS among non-Hispanic white cohort and found that R47H variant 
was more frequent in ALS patients than healthy controls (odds ratio=2.40, p=4.1×10−3), indicating 
R47H may be a significant risk factor [93]. In a Caucasian cohort, TREM2 R47H was found 
significantly associated with increased risk of FTD (odds ratio=5.06, p=0.001) and PD (odds 
ratio=2.67, p=0.026) [94]. However, in European population, Lill and colleague failed to find 
consistent evidence for association between R47H variant and PD (odds ratio=1.36, p=0.0767) or 
ALS (odds ratio=1.41, p=0.198) [95]. Similarly, TREM2 R47H variant was not seen in sporadic 
ALS patients in a Chinese cohort [96]. 
Although there is no consistent conclusion about the relationship between TREM2 rare 
variants and risks of certain diseases, the role of TREM2 in CSN degeneration and microglial 
function has been established. Since some of these neurodegenerative diseases are very rare in the 
population, larger-scale studies in different population are difficult but still necessary and required 
for a better understanding. 
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7.0 Diagnostic and Therapeutic Targeting of TREM2: Opportunities and Challenges 
To date, there is no treatment or medicine for preventing or slowing AD. As discussed 
above, TREM2 plays an important role in modulating microglia function, activation, lipid 
metabolism and immune response, thus leading to a lot of research on therapeutic targeting of 
TREM2. Some studies proposed that enhancing TREM2 levels or activities might be beneficial in 
AD treatment. It is reported that RXR can upregulate the expression of TREM2 and DAP12 [22, 
23], although the mechanism remains unclear. Treatment of RXR agonist, such as bexarotene, was 
found to increase the expression of TREM2 mRNA in the cortex of AD mice [23]. An in vivo 
study reported that overexpression of TREM2 markedly improve cognition in the brain of APPPS1 
mice (7-month), indicating increased TREM2 expression generates positive response to the disease 
progression. But this effect was abolished with overexpression of TREM2 in aged (18-month) 
APPPS1 mice [97, 98]. Brain section from AD patients with R47H variant had less microglia 
barrier around plaques, and it is proposed that TREM2-stimulating antibodies which can activate 
ERK and calcium pathway thus improving migration of microglia [53]. In addition to full-length 
TREM2, studies have demonstrated a protective role of sTREM2 to AD and as a potential 
biomarker of AD, while the mechanisms are not clear. Studies reported that sTREM2 promotes 
cell survival through activating extracellular signal-regulated kinases 1/2 and mitogen-activated 
protein kinase 14 [41]. Significant higher sTREM2 levels were observed in AD patients than case-
matched controls. Positive correlation was found between sTREM2 levels in CSF and tau, but not 
Aβ, indicating the effects of sTREM2 depend on disease stages [46, 47]. 
However, there are still several concerns about TREM2 as a potential therapeutic target. 
Firstly, as reported, frequency of these TREM2 rare variants is less than 1% in the population, 
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while APOE4 accounts for about 20%. It is much less efficient to target TREM2 as a potential 
therapeutic strategy. For non-carriers, which are the majority of AD patients, there is no guarantee 
that TREM2-based therapeutic strategy will be effective for them. Secondly, the timing of 
TREM2-based treatment is important. It is ideal to activate TREM2 at early stage of the disease, 
along with the start of Aβ accumulation or even before, because normal or enhanced microglia 
activation would be beneficial to Aβ clearance, thus slowing down the disease progression. 
Thirdly, it remains unclear that how to target TREM2 in human. Further studies are required on 
TREM2-stimulting antibodies, because such activity might impair the ligands-binding of TREM2 
[32]. Increasing TREM2 expression levels is proved to improve phagocytosis and reduce 
inflammation. However, overexpression of TREM2 through lentiviral approaches is impossible in 
human because of a high possibility of generating oncogenic transformation. In addition, 
expression of TREM2 outside the CNS is different and not only by microglia. We need to be aware 
of any unwanted or harmful side effects. Lastly, considering sTREM2 as a biomarker of the 
disease, only the CSF sTREM2 level is useful, but not plasma levels. Test of CSF biomarker levels 
is not suitable for primary care. 
Collectively, targeting of TREM2 is a promising strategy for AD treatment or medicine. 
However, there still exist some challenges that need further study and test. 
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